机构：[1]McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal H4H IR3, Canada[2]Innovation Center for Neurological Disorders, Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China神经内科[3]Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing 100053, China[4]Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing 100053, China[5]Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing 100053, China[6]Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing 100053, China[7]National Clinical Research Center for Geriatric Disorders, Beijing 100053, China[8]Institut Universitaire de Gériatrie de Montréal, Montréal H3W IW5, Canada[9]Department of Medical Genetics, University of British Columbia, Vancouver V6T IZ4, Canada[10]Division of Neurology, Department of Medical Genetics, University of British Columbia, Vancouver V6T IZ4, Canada[11]Division of Neurology/Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto M5S 3H7, Canada[12]Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto M4N 3M5, Canada[13]Montreal Neurological Institute, Montréal H3A 2B4, Canada[14]Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China神经内科
As biomarkers are important in the early diagnosis of Alzheimer's disease (AD), the first collab-orative work of recruiting early-onset familial AD (EO-FAD) families in Canada and China was initiated in 2012. The registration networks have collected hundreds of pedigrees, for which genetic screening, neuropsycholog-ical tests and amyloid and tau imaging was used to study diagnostic biomarkers for preclinical and mild cognitive impairment (MCI) stages of AD. Besides identifying ped-igrees with novel mutations in presenilins (PSENs)/amy-loid precursor protein (APP), the program has benefited training of Chinese research fellows, AD clinical trials for prevention, the ethical concerns for clinical findings, and other collaborative projects with Chinese investiga-tors. Further research of the collaborative program may facilitate the testing and clinical use of novel treatments for EOFAD and late onset AD and contribute to dementia prevention strategies in Canada and China.
语种：
外文
第一作者：
第一作者机构：[1]McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal H4H IR3, Canada
通讯作者：
通讯机构：[1]McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal H4H IR3, Canada
推荐引用方式(GB/T 7714)：
Serge Gauthier,Jianping Jia,Sylvie Belleville,et al.Perspectives on a collaborative Canada-China research program on diagnostic biomarkers for pre-dementia stages of Alzheimer's disease[J].转化神经科学电子杂志（英文）.2017,2(3):1-6.doi:10.3868/j.issn.2096-0689.2017.03.001.
APA：
Serge Gauthier,Jianping Jia,Sylvie Belleville,Simon Cloutier,Dessa Sadovnick...&Pedro Rosa-Neto.(2017).Perspectives on a collaborative Canada-China research program on diagnostic biomarkers for pre-dementia stages of Alzheimer's disease.转化神经科学电子杂志（英文）,2,(3)
MLA：
Serge Gauthier,et al."Perspectives on a collaborative Canada-China research program on diagnostic biomarkers for pre-dementia stages of Alzheimer's disease".转化神经科学电子杂志（英文） 2..3(2017):1-6
